FDA.reportPublic FDA data

Application 125085

Type
BLA
Sponsor
GENENTECH

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001AVASTINBEVACIZUMABVIAL; INTRAVENOUS100MGNoNo
002AVASTINBEVACIZUMABVIAL; INTRAVENOUS400MGNoNo

NDC Listings For This Application#

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
50242-060AvastinbevacizumabGenentech, Inc.BLACurrent
50242-060AvastinbevacizumabGenentech, Inc.BLACurrent
50242-060AvastinbevacizumabGenentech, Inc.BLACurrent
50242-060AvastinbevacizumabGenentech, Inc.BLACurrent
50242-060AvastinbevacizumabGenentech, Inc.BLACurrent
50242-060AvastinbevacizumabGenentech, Inc.BLACurrent
50242-060AvastinbevacizumabGenentech, Inc.BLACurrent
50242-060AvastinbevacizumabGenentech, Inc.BLACurrent
50242-060AvastinbevacizumabGenentech, Inc.BLACurrent
50242-060AvastinbevacizumabGenentech, Inc.BLACurrent
50242-061AvastinbevacizumabGenentech, Inc.BLACurrent
50242-061AvastinbevacizumabGenentech, Inc.BLACurrent
50242-061AvastinbevacizumabGenentech, Inc.BLACurrent
50242-061AvastinbevacizumabGenentech, Inc.BLACurrent
50242-061AvastinbevacizumabGenentech, Inc.BLACurrent
50242-061AvastinbevacizumabGenentech, Inc.BLACurrent
50242-061AvastinbevacizumabGenentech, Inc.BLACurrent
50242-061AvastinbevacizumabGenentech, Inc.BLACurrent
50242-061AvastinbevacizumabGenentech, Inc.BLACurrent
50242-061AvastinbevacizumabGenentech, Inc.BLACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
74718SUPPL 2023-07-11
72113SUPPL2022-09-20
72106SUPPL2022-09-19
71473SUPPL2022-06-28
69508SUPPL2021-12-07
65606SUPPL2020-12-17
65554SUPPL2020-12-09
64905SUPPL2020-10-14
64895SUPPL2020-10-14
64807SUPPL2020-10-02
64784SUPPL2020-10-01
63379SUPPL2020-06-02
63354SUPPL2020-05-29
59156SUPPL2019-06-21
59148SUPPL2019-06-21
58656SUPPL2019-05-13
54603SUPPL2018-06-14
54544SUPPL2018-06-13
53995SUPPL2018-05-03
53984SUPPL2018-05-02
50627SUPPL2017-12-07
50626SUPPL2017-12-07
46099SUPPL2016-12-08
46088SUPPL2016-12-08
18782SUPPL2015-12-02
9600SUPPL2015-12-02
39831SUPPL2015-10-07
9599SUPPL2015-10-01
31824SUPPL2015-05-11
39830SUPPL2015-05-08
9598SUPPL2014-11-17
18781SUPPL2014-11-14
39829SUPPL2014-09-03
31822SUPPL2014-09-03
44791SUPPL2014-08-19
31823SUPPL2014-08-15
18780SUPPL2014-08-14
31821SUPPL2013-12-17
18779SUPPL2013-12-17
18778SUPPL2013-04-01
31820SUPPL2013-03-28
31819SUPPL2013-01-25
39828SUPPL2013-01-24
18777SUPPL2012-11-28
9597SUPPL2012-11-23
9595SUPPL2012-10-29
39827SUPPL2012-10-26
9594SUPPL2012-05-08
18776SUPPL2012-05-07
9596SUPPL2011-12-27
9593SUPPL2011-10-04
18775SUPPL2011-09-30
22782SUPPL2011-02-15
9592SUPPL2011-02-15
31818SUPPL2011-01-10
44427ORIG2009-12-11
31816SUPPL2009-08-06
39826SUPPL2009-08-04
31817SUPPL2009-05-13
18774SUPPL2009-05-05
31815SUPPL2008-03-28
39825SUPPL2008-03-27
9591SUPPL2008-02-27
39824SUPPL2007-09-26
39823SUPPL2006-10-23
31814SUPPL2006-10-23
22781SUPPL2006-10-11
39822SUPPL2006-09-25
9590SUPPL2006-09-25
31813SUPPL2006-06-27
18773SUPPL2006-06-21
43303SUPPL2006-06-20
31812SUPPL2006-04-21
18772SUPPL2006-04-21
9589SUPPL2005-10-20
39821SUPPL2005-09-30
22780ORIG2005-01-28
31811ORIG2004-02-27
18771ORIG2004-02-27